The prevalence of heart failure (HF) continues to rise in developed nations. Symptomatic congestion is the most common reason for patients to seek medical attention, and management often requires intravenous (IV) diuretic administration in the hospital setting. Typically, the number of admissions increases as the disease progresses, not only impacting patient survival and quality of life but also driving up healthcare expenditures. pH-neutral furosemide delivered subcutaneously using a proprietary, single-use infusor system (Furoscix) has a tremendous potential to transition in-hospital decongestive therapy to the outpatient setting or to the patient’s home. This review is aimed at providing an overview of the pharmacodynamic and pharmacokinetic profile of the novel pH-neutral furosemide in addition to the most recent clinical trials demonstrating its benefit when used in the home setting. Given the newest data and approval by the Food and Drug Administration in the US, it has the potential to revolutionize the care of patients with decompensated HF. Undoubtedly, it will lead to improved quality of life as well as significantly reduced healthcare costs related to hospital admissions.

在发达国家，心力衰竭（HF）的患病率持续上升。有症状的充血是患者就医的最常见原因，治疗通常需要在医院进行静脉注射 (IV) 利尿剂。通常，随着疾病的进展，入院人数会增加，这不仅会影响患者的生存和生活质量，还会增加医疗支出。pH 中性的呋塞米使用专有的一次性输液器系统 (Furoscix) 皮下输送，具有将院内减充血治疗转移到门诊或患者家中的巨大潜力。本综述旨在概述新型 pH 中性呋塞米的药效学和药代动力学特征，以及最近的临床试验证明其在家庭环境中使用时的益处。鉴于最新数据以及美国食品和药物管理局的批准，它有可能彻底改变失代偿性心力衰竭患者的护理。毫无疑问，这将提高生活质量，并显着降低与住院相关的医疗费用。